Great Basin Scientific Inc (NASDAQ:GBSN) a molecular diagnostics firm reported that Dr. Suzette Chance has received a 2017 “Women Worth Watching®” in STEM Award. It is being awarded by Profiles in Diversity Journal, a publication which is dedicated to advancing and promoting diversity and inclusion in the government, corporate, STEM, nonprofit, and higher education divisions. Dr. Chance made a place in 45 women countrywide to get the reward, which is a development of the Women Worth Watching awards program.
Rob Jenison, the SVP, R&D and CTO of Great Basin, reported that since Suzette joined company, she has propelled the FDA submissions and clinical trials for last three assays, one of which is commercially available, while two others expecting FDA clearance, an achievement that is nothing short of outstanding.
Her commitment to quality, professionalism and previous success in managing clinical studies has had a considerable impact on the firm’s success in progressing the build-out of product menu. They are extremely delighted to have Suzette on their team and commend her on this recognition.
Dr. Chance has been with Great Basin since February 2016 with more than 20 years of extensive experience in in vitro diagnostics, coordinating with clinical and regulatory affairs and also on product design and innovation. Prior to this role, she had been on senior leadership profiles with Immucor GTI Diagnostics, Genetic Testing Institute and Gen-Probe/Hologic.
Dr. Chance began her career as a biochemist and scientist with DuPont Medical Products, where she advanced and established a latest bio-analytical lab for the DuPont facility. She completed her B.S. in biochemistry from the University of Minnesota and Ph.D. in biochemistry from Johns Hopkins University. Dr. Chance has been a part of development course of three patents. She even co-authored as many as 13 published papers.
Expressing about her view about diversity in STEM segments, Dr. Chance reported that diversity across STEM industries is vital in driving advancement and innovation.